LENZ Therapeutics (LENZ) Current Assets (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Current Assets of $268.4 million for Q1 2026, up 35.64% year-over-year from $197.9 million in Q1 2025, and down 10.96% quarter-over-quarter from $301.4 million in Q4 2025.
LENZ Therapeutics (LENZ) Current Assets (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Current Assets for 7 consecutive years, with $268.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 35.64% year-over-year to $268.4 million; the TTM figure through Mar 2026 stood at $268.4 million (up 35.64% YoY), while the FY2025 annual figure was $301.4 million, up 42.23% from the prior year.
- Current Assets slipped to $268.4 million in Q1 2026 per LENZ's latest filing, from $301.4 million in the prior quarter.
- Across five years, Current Assets topped out at $343.8 million in Q1 2022 and bottomed at $67.2 million in Q4 2023.
- Historically, Current Assets has averaged $241.7 million across 5 years, with a median of $238.8 million in 2023.
- Annual changes were most pronounced in 2023 — Current Assets plunged 75.58% — and 2024, when it soared 215.15%.
- LENZ Therapeutics' Current Assets stood at $275.4 million in 2022, then slumped by 75.58% to $67.2 million in 2023, then jumped by 215.15% to $211.9 million in 2024, then soared by 42.23% to $301.4 million in 2025, then decreased by 10.96% to $268.4 million in 2026.
- Business Quant data shows LENZ's Current Assets at $268.4 million in Q1 2026, $301.4 million in Q4 2025, and $207.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | LENZ Therapeutics | 148.40 Mn | 148.40 Mn | 5.21 Mn | 233.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233.28 Mn |
| Mar 31, 2026 | 268.37 Mn |
| Dec 31, 2025 | 301.41 Mn |
| Sep 30, 2025 | 207.00 Mn |
| Jun 30, 2025 | 213.60 Mn |
| Mar 31, 2025 | 197.86 Mn |
| Dec 31, 2024 | 211.92 Mn |
| Sep 30, 2024 | 220.70 Mn |
| Jun 30, 2024 | 199.35 Mn |
| Mar 31, 2024 | 216.67 Mn |
| Dec 31, 2023 | 67.24 Mn |
| Sep 30, 2023 | 238.78 Mn |
| Jun 30, 2023 | 251.17 Mn |
| Mar 31, 2023 | 270.31 Mn |
| Dec 31, 2022 | 275.37 Mn |
| Sep 30, 2022 | 298.49 Mn |
| Jun 30, 2022 | 326.64 Mn |
| Mar 31, 2022 | 343.76 Mn |
| Dec 31, 2021 | 381.74 Mn |
| Sep 30, 2021 | 401.23 Mn |